RxDoctor Payments DataLook up a doctor →

Andrea Natale, MD

Clinical Cardiac Electrophysiology · Austin, TXNPI 1841382421

Payments from drug & device makers

$7,782,026in general payments, 2019–2025

Across 2,531 payments — averaging $3074.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$3.7M
  • Boston Scientific$1.7M
  • Medical Device Business Services, Inc.$762K
  • Medtronic$602K
  • Abbott$365K
  • Philips North America LLC$128K
  • plus $592K from 37 others

What the payments were for

  • Consulting fees$640,81548%
  • Speaking & faculty fees$357,08627%
  • Travel & lodging$234,99517%
  • Food & beverage$72,0425%
  • Education$410%
  • Entertainment$1170%
  • Ownership interest$38,1963%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,782,026 in reported general payments places this provider in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$461,855
Medicare patients
511
Services billed
2,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$303,541
XareltoRivaroxaban109$87,005
MultaqDronedarone Hcl47$42,429
Flecainide Acetate67$2,022
Colchicine55$1,401
Enoxaparin Sodium11$829
Potassium Chloride105$736
Metoprolol Succinate57$716
Propafenone Hcl14$512
SotalolSotalol Hcl35$402
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$298
Metoprolol Tartrate42$203
Tamsulosin Hcl51$152
Furosemide120$151
Finasteride47$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8,397$303,541309 claims
Johnson & JohnsonXarelto$1,192$87,005109 claims
Sanofi-aventis U.S. LLCMultaq$14,348$42,42947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →